Zymeworks (ZYME) stock price, chart and financials
Price chart
Company profile
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Frequently asked questions
How do I buy stock in Zymeworks (ZYME)?
ZYME trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web dashboard at portal.lighthorse.io, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.
Quotes and charts are not real-time and must not be relied on for trade decisions or valuation.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.